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220Limiting the Daily Total Nucleated Cell Dose
of Cryopreserved Peripheral Blood Stem Cell
Products for Autologous Transplantation Improves
Infusion-Related Safety with No Adverse Impact
on Hematopoietic Engraftment
Nandita Khera,1 Jack Jinneman,2 Barry E. Storer,1 Shelly Heimfeld,1
Megan M. O’Meara,1 Thomas R. Chauncey,1,3 Stephanie J. Lee,1 Michael Linenberger1Cryopreserved peripheral blood stem cell (PBSC) products can induce a number of infusion-related adverse
reactions, including life-threatening cardiac, neurologic, and other end-organ complications. Preliminary anal-
yses suggested limiting the daily total nucleated cell dose infused might decrease the incidence of these
adverse effects. A policy change implemented in December 2007, limiting the total nucleated cell (TNC)
dose to\1.63  109 TNC/kg/day, allowed us to assess the impact of this intervention on infusion-related
safety, infusion schedules, engraftment, and costs in cohorts of patients undergoing autologous stem cell
transplants (ASCTs) 2 years before (325 ASCTs in 288 patients) and 2 years after the policy change
(519 ASCTs in 479 patients). The percentage of autologous transplant patients requiring multiple day infu-
sions increased from 6% to 24%. Concurrently, the incidence of infusion-related grade 3-5 severe infusion-
related adverse events (SAEs) decreased significantly, from 4% (13 of 325) prepolicy change to 0.6% (3 of 519)
postpolicy change (P\.0004). Multiday infusions were not associated with increased time to neutrophil or
platelet engraftment or the costs of transplantation. We conclude that limiting the daily TNC dose improved
the safety of this procedure without compromising engraftment or increasing the costs of the procedure.
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Cryopreserved peripheral blood stem cellsINTRODUCTION
High-dose chemotherapy with autologous stem
cell transplantation (ASCT) remains a common treat-
ment approach in multiple myeloma and lymphoma.
Peripheral blood progenitor cells are used most
commonly as a graft source for autologous transplants.
When a patient undergoes ASCT, CD341 stem cells
are mobilized into the peripheral blood, harvested
by apheresis, and cryopreserved, to be thawed and1Clinical Research Division, Fred Hutchinson Cancer
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6/j.bbmt.2011.06.003reinfused after administration of high-dose ablative
chemotherapy with or without radiotherapy. Infusion
of cryopreserved autologous stem cell products has
been associated with adverse reactions. These range
from mild events, such as nausea/vomiting, hypoten-
sion or hypertension, abdominal cramps, diarrhea,
flushing, and chills, to severe life-threatening events
such as cardiac arrhythmia, encephalopathy, acute re-
nal failure, and respiratory depression [1-22]. These
reactions have been attributed to the cryoprotectant,
dimethyl sulfoxide (DMSO) [3,7,14,15], red cell
hemolysate [19-21], bacterial contamination of stem
cell product [12,22], high numbers of infused total
nucleated cells (TNCs) and granulocytes [8,16-18],
or to idiosyncratic reactions.
Severe infusion-related adverse events (SAEs)
occurred in 3 patients receiving cryopreserved periph-
eral blood stem cell (PBSC) products for ASCT
between August 2005 and October 2007 in our pro-
gram. Investigation of these cases suggested a possible
causal association with high TNC and/or granulocyte
content of the cryopreserved PBSC products; thus, our
Biol Blood Marrow Transplant 18:220-228, 2012 221Safety of Autologous PBSC Product Infusionsinstitutional experience with infusion-related AEs was
reviewed, and a policy change was implemented in
December 2007 to establish infusion limits. The new
policy limited the daily cryopreserved PBSC product
cell dose to #1.63  109 TNC/kg/day (in addition
to the standard 10 mL/kg/day total volume restriction
to limit the amount of DMSO) in an effort to avoid/
reduce the severity of infusion-related SAEs. The
purpose of the current study was to assess the impact
of this institutional policy change on cryopreserved
PBSC product infusion schedules, neutrophil and
platelet engraftment, and infusion-related safety
outcomes and costs of the transplantation.MATERIALS AND METHODS
Retrospective Analysis of Infusion-Related SAEs
and Institutional Policy Change
Three patients undergoing ASCT in 2007 devel-
oped infusion-related SAEs during or shortly after re-
ceiving thawed autologous cryopreserved PBSC
product for multiple myeloma, non-Hodgkin lym-
phoma, and Hodgkin’s lymphoma (Table 1). The
thawed, unmanipulated PBSC products were infused
after intravenous prehydration and administration of
premedication with diphenhydramine and hydrocorti-
sone, per institutional guidelines. Because these SAEs
were temporally related to cryopreserved product in-
fusions and did not appear to be causally associated
with excessive DMSO exposure, anaphylaxis, haemol-
ysis, concurrent infection, or an other direct cause,
a quality assurance investigation was performed to de-
termine whether infusion-related SAEs might be
associated with a high cellular content in the product,
as had been recently reported by others [6,8,16,17].
For this quality investigation, infusion-related AEs
were those that occurred within 4 hours postinfusion,
and were reported on the Cellular Therapy Labora-
tory (CTL) InfusionMonitoring Form. The Common
Terminology Criteria for Adverse Events, version 3.0Table 1. Index Cases with Severe Infusion-Related Adverse Events
Patient History SAE
Volume a
of
I 48/F; plasma cell leukemia;
multiple infections;
2nd HCT
Rapid multiorgan failure;
death 30 hours after
infusion
466 m
II 59/M; recurrent lymphoma;
cardiovascular disease
(2-day PBSC infusion)
2nd day of infusion:†
myocardial infarction
and death
(2nd da
550 m
III 60/M; refractory
Hodgkin’s lymphoma;
cardiovascular disease
Acute renal failure;
hemodialysis
766 mL
HCT indicates hematopoietic cell transplantation; PBSC, peripheral blood ste
*All product parameters are based on prefreeze product.
†Received 596 mL of PBSC cryoproduct on the first day.
‡Did not exceed the 10 mL/kg DMSO limit.was used to grade acute conditions that were tempo-
rally associated with the infusions, and the software
distinguished grades 1 through 5, with grade 1, mild;
grade 2, moderate; grade 3, severe; grade 4, life-
threatening/disabling; and grade 5, death because of
the AE [23]. The association of distribution of the
grades of the AEs with the total infused volume of cry-
opreserved PBSC product/kg recipient weight, the cu-
mulative prefreeze TNC content of all product bags,
and the cumulative TNC/kg was evaluated. The pre-
freeze granulocyte content of PBSC products are not
routinely quantified; however, analyses of a subset of au-
tologous PBSC products revealed that the granulocyte
content typically ranged from 40% to 70% of the
TNC content, which is consistent with other centers
using similar apheresis instruments and methodologies
[24]. A total of 411 patients who received PBSC cryo-
product infusions for ASCT from January 3, 2006, to
October 31, 2007, were reviewed. Median and quartile
analyses identified the prefreeze TNC/kg dose as the
strongest predictor of SAEs, with 67% of SAEs (grade
3 or higher) (Figure 1) occurring in the highest quartile
of patients who received$1.63 109 TNC/kg/day. Al-
though product DMSO exposure (up to a maximum of
1 g/kg/day or 10 mL/kg/day of product frozen in 10%
DMSO, per institutional guidelines) also increased with
greater numbers of PBSC product bags and TNCs in-
fused, this parameter was not as strongly predictive of
infusion-related SAEs as the TNC/kg (data not shown).
Based on this quality assessment review, our SAE cases,
and the recent published reports of infusion-relatedAEs
being independently associated with high TNC and
granulocyte exposure, an institutional policy change
was adopted to split infusions to deliver #1.63  109
TNC/kg/day. This policy change was implemented
on December 4, 2007.
Patients and Study Design to Assess the Impact
of the Policy Change
A retrospective cohort study was undertaken to
assess the impact of the policy change to limit the(SAEs)
nd Number
Bags CD34+ Cells/kg* TNC/kg*
Granulocytes/kg
(% TNC)*
L 8 bags 5.17  106 3.05  109 2.29  109 (65.4%)
y product)
L 10 bags
(2nd day product)
1.3  106
3.75  109 2.03  109 (54.13%)
‡ 12 bags 5.57  106 6.14  109 4.64  109 (75.57%)
m cell; TNC, total nucleated cell.
Figure 1. Distribution of adverse events according to grades in quar-
tiles based on TNC/kg. Each of the grades (1, 2, 3-5) sums to 100%
over the 4 quartiles (Q1 1 Q2 1 Q3 1 Q4).
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for ASCT patients on infusion-related safety, engraft-
ment, and costs. The study was designed to compare
outcomes in a cohort of patients undergoing infusion
of cryopreserved PBSC products for ASCTs from
May 20, 2006, to December 4, 2007, (prepolicy
change) to a cohort of ASCTs from December 5,
2007, to December 31, 2009, (postpolicy change).
This retrospective cohort study was approved by the
institutional review board of the Fred Hutchinson
Cancer Research Center.
Seven hundred sixty-seven patients were included
in the study. These patients underwent a total of 844
ASCTs at 4 different centers including the University
of Washington Medical Center (UWMC), Seattle
Cancer Care Alliance (SCCA), Seattle Children’s Hos-
pital, and Veteran’s Administration Puget Sound
Health Care System. Patients who received multiple
days of PBSC cryoproduct infusions because of
protocol requirement, rather than because of DMSO
content or total number of infused TNC/kg, were ex-
cluded from the study. All patients received thawed
PBSC products that were not diluted, washed, or oth-
erwise manipulated. Intravenous prehydration and
premedications were routinely given. Infusion moni-
toring forms recorded either no infusion-related AEs
during 4 hours postinfusion or AEs associated with
specific signs and/or symptoms. Nursing and treat-
ment interventions were also recorded. For CTL qual-
ity assurance purposes, additional clinical information
was routinely obtained to formally investigate AEs of
grade 3 or greater.
PBSC Collection and Product Parameters
All patients had undergone collection of mobilized
PBSCs by the SCCAApheresisUnit.Mononuclear cell
apheresis was performed on all patients using the
COBE Spectra instrument (CaridianBCT, Lakewood,
CO) with the white blood cell (WBC) kit and manual
V4.7 program, processing 3 to 6 times total blood vol-
ume, as previously described [25]. Apheresis collectionscommenced when the blood CD34 count reached at
least 5-10  106/L or the WBC count had recovered
to 1  109/L following mobilization with granulocyte
colony-stimulating factor (G-CSF) and preceding che-
motherapy, or on day 4 or 5 when mobilized from
steady state with G-CSF alone. A few patients received
plerixafor in addition toG-CSF formobilization. Daily
apheresis continued until $5  106 CD341 cells/kg
were collected for a single ASCT or at least 2.5  106
CD341 cells/kg if the patient was difficult to mobilize.
Before concentration and cryopreservation in 10%
DMSO, the TNC content, viability, and sterility of
the PBSC products were routinely determined. As
with the prior quality assurance investigation, the gran-
ulocyte contents of autologous PBSC products were
not routinely quantified before cryopreservation. To
confirm our preliminary observations of the range of
PBSC product granulocyte content and to determine
whether the product quality had changed over time,
we accessed archival prefreeze flow cytometry data on
a random subset of products from both the pre and
post-policy change cohorts to enumerate granulocyte
content in relation to TNC content.
Data Collection
The CTL product records and infusion monitor-
ing forms were reviewed to retrieve information about
patient age and diagnosis, the location, and date(s) of
autologous cryopreserved PBSC product infusion, cu-
mulative product volumes, number of bags infused,
clinical infusion-related AEs with grades, and addi-
tional information based on internal CTL quality in-
vestigations. The CTCAEv3.0 was used to grade
acute conditions that were temporally associated with
the infusions, as outlined above. For the purpose of
the study, any AEs grade 3 and above were termed as
SAEs. Product cumulative CD341 cell counts,
CD341 cells/kg, cumulative product TNC counts,
and TNC/kg, neutrophil, and platelet engraftment
data were extracted from the electronic medical re-
cords as well as an institutional database. Costs were
retrieved from the accounting database for the SCCA
and UWMC patients for whom charges and depart-
ment ratio of costs to charges (RCCs) for the first 3
months after the transplantation were available.
Statistical Analysis
Results are expressed as median (range) for contin-
uous variables and counts (percentages) for categoric
variables. For purposes of display and analysis, each
ASCT is counted as a separate data point, although
some patients experienced more than 1 ASCT. Statis-
tical comparison between prepolicy and postpolicy
change was performed using the Wilcoxon rank-sum
test for continous variables and the chi-square test
for categoric variables. All P values are 2 sided.
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Study Population
Study cohorts included 288 patients undergoing
325 ASCTs (261 with 1 ASCT, 21 with 2, 2 with 3,
and 4 with 4) before the policy change and 479 patients
undergoing 519 ASCTs (446 with 1 ASCT, 28 with 2,
3 with 3, and 2 with 4) after the policy change. Table 2
compares the patient and transplant characteristics in
the overall pre and post-policy cohorts and in the sub-
set of patients with cryopreserved PBSC products that
contained .1.63  109 TNC/kg. There were no sig-
nificant differences in the age, gender, distribution of
diagnosis, and product TNC and CD341 cell counts
between the high TNC cohorts pre and post-policy
change. The median volume/kg/day was lower for
the post-policy group compared with pre-policy both
for overall cohort (P 5 .003) and the high TNC sub-
group (P\.001). However, the median total volume
per ASCT was similar in pre and post-policy cohorts
both for overall and high TNC subgroups. The fre-
quencies of patients with cryopreserved products con-
taining a cumulative TNC content of .1.63  109/kg
were similar in the pre-policy and post-policy cohorts
(25.2% and 24.1%, respectively). The quartile distri-
butions of cryopreserved product granulocyte contents
were no different for PBSC products collected and
stored from patients in the prepolicy and postpolicyTable 2. Patient and Transplant Characteristics
(A)
Prepolicy Change (n 5 32
Age at ASCT, years, median (range) 53 (1-78)
Male, n (%) 230 (71)
Weight, median (range) 81.1 (10.6-165.0)
Diagnosis, n (%)
Multiple myeloma 118 (36)
Non-Hodgkin lymphoma/CLL 119 (37)
Other diagnoses 88 (27)
CD34  106/kg, median (range) 6.29 (0.22-59.25)
TNC  109/kg, median (range) 0.82 (0.09-8.65)
Volume (mL)/kg/day, median (range) 1.75 (0.26-9.27)
Volume (mL) /kg total, median (range) 1.80 (0.26-16.78)
(B)
Prepolicy Change (n 5 82
Age at ASCT, years, median (range) 57 (2-75)
Male, n (%) 56 (68)
Weight, median (range) 78.9 (15.1-137.8)
Diagnosis, n (%)
Multiple myeloma 20 (24)
Non-Hodgkin lymphoma/CLL 44 (54)
Other diagnoses 18 (22)
CD34  106/kg, median (range) 4.98 (1.11-25.8)
TNC  109/kg, median (range) 2.66 (1.64-8.64)
Volume (mL)/kg/day, median (range) 4.54 (1.13-9.27)
Volume (mL)/kg total, median (range) 5.29 (2.26-16.78)
CLL indicates chronic lymphocytic leukemia; TNC, total nucelated cell.
(A) All autologous stem cell transplants (ASCTs) during the study period. (B) A
dose of >1.63  109/kg.cohorts (Table 3). Together, these parameters indi-
cated that apheresis collection quality and the cellular
composition of the cryopreserved PBSC products had
not changed appreciably over the course of the study
period. There were no significant changes in the prac-
tices for stem cell collection or processing, clinical pol-
icies for reinfusion of cryopreserved PBSCs, and for
tracking of AEs over the study period.
Number of Infusion Days
The median number of infusion days was 1 versus
1 for all patients, and 1 versus 2 for those with
.1.63 109 TNC/kg product cell doses (P\ .0001).
The percentage of patients requiring 1, 2, or .2 days
of infusion before the policy change was 93.6%,
5.8%, and 0.6%, respectively, whereas it was
76.5%, 16.0%, and 7.5% after the policy change
(P\ .0001).
Infusion-Related AEs and Time to Engraftment
There was no difference in the incidence of all
grades of infusion-related AEs in the postpolicy
cohort, but the number of ASCTs with grade 3-5
AEs was significantly reduced after the policy change.
This was true among all autologous transplants (4%
pre-policy change vs 0.6% post-policy change,
respectively, P \ .0004) and among the subset
of ASCTs with cryopreserved PBSC products5) Postpolicy Change (n 5 519) P Value
55 (0-74) .02
342 (66) .14
81.8 (7.5-158.8) .55
225 (43)
175 (34)
119 (23) .12
6.35 (0.81-87.04) .49
0.92 (0.05-7.26) .43
1.68 (0.30-7.61) .003
1.80 (0.30-10.49) .88
) Postpolicy Change (n 5 125) P Value
60 (2-73) .32
73 (58) .15
72.3 (14.8-121.7) .69
45 (36)
61 (49)
19 (15) .16
5.00 (0.81-53.6) .64
2.53 (1.63-7.26) .90
2.37 (1.00-7.61) <.0001
5.11 (2.00-10.49) .81
SCTs with cryopreserved PBSC products containing a cumulative TNC
Table 3. Pre and Post-policy Change Granulocye Contents of Prefreeze Apheresis Products
TNC/kg Quartiles
Prepolicy Change Postpolicy Change
P ValueN Granulocytes/kg (109) Median (range) N Granulocytes/kg (109) Median (range)
Q1 (TNC/kg < 0.49) 20 0.22 (0.04-0.33) 16 0.25 (0.07-0.41) .31
Q2 (TNC/kg 0.49-0.82) 18 0.38 (0.18-0.54) 19 0.34 (0.03-0.56) .83
Q3 (TNC/kg 0.83-1.63) 19 0.62 (0.38-1.00) 19 0.58 (0.18-0.97) .59
Q4 (TNC/kg >1.63) 18 1.23 (0.66-5.54) 19 1.45 (0.60-3.23) .46
TNC indicates total nucleated cell.
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P 5 .002) (Table 4). Ten of the 125 ASCTs with
products containing .1.63  109 TNC/kg in the
postpolicy cohort received all of their cells on 1 day
(Table 4B). The decision for a single-day infusion
was made predominantly because the cumulative TNC
content only minimally exceeded the 1.63  109/kg
limit.
There were 3 SAEs in the post-policy change co-
hort. Two of those had received products containing
#1.63  109 TNC/kg. One of them was a patient
with a known seizure disorder who developed a self-
limited, partial complex seizure at the end of infusion
and was subsequently found to have subtherapeutic
blood levels of antiseizure medication. The second pa-
tient had transient chest pain that required brief hospi-
talization to rule out a myocardial infarction. No
etiology was determined, and the patient suffered no
sequelae. The third event was in a pediatric patient,
who received a product with .1.63  109 TNC/kg
and ultimately suffered a grade 4 adverse event.
To determine whether the significant difference
in post-policy SAE incidence was because of the differ-
ence in TNC/kg/day or DMSO volume per day, aTable 4. Clinical Outcomes
(A)
Pre-policy
>1 infusion days, n (%) 21
Infusion AEs (any grade), n (%) 149
Infusion AEs (grade 3-5), n (%) 13
Days to neutrophil engraftment, median (range), [n evaluable]† 14
Days to platelet engraftment, median (range), [n evaluable]† 12
(B)
Pre-policy
>1 infusion days, n (%) 20
Infusion AEs (any grade), n (%) 60
Infusion AEs (grade 3-5), n (%) 8
Days to neutrophil engraftment, median (range), [n evaluable]† 14
Days to platelet engraftment, median (range), [n evaluable]† 13
TNC indicates total nucleated cell; AE, adverse event.
(A) All patients undergoing autologous transplantation during the study period
TNC dose of >1.63  109/kg.
*The few patients in this group who received 1 day of infusion generally had PB
†All patients could not be evaluated because of death or missing data becauselogistic regression analysis was performed. Product
volume alone was a significant predictor of infusion-
related SAEs (P\.0001), but this parameter lost
significance when adjusted for TNC/kg (P 5 .54).
By comparison, TNC/kg was a highly significant pre-
dictor for AEs in both univariate analysis (P\.0001)
and when adjusted for product volume (P\.0001).
The policy change did not have any apparent det-
rimental impact on neutrophil or platelet engraftment.
The median days to neutrophil engraftment were the
same for the overall pre-policy and post-policy cohorts
(14 vs 14, P 5 .99) and for ASCTs with cryopreserved
products containing cumulative TNC doses of .1.63
 109/kg (14 vs 14, P 5 .12) (Table 4). Similarly, no
differences were seen in the median days to platelet en-
graftment in either the overall cohorts (12 vs 12, P 5
.82) or among those who received TNC doses of
.1.63  109/kg (13 vs 13, P 5 .82) (Table 4). Times
to neutrophil and platelet engraftment within sub-
groups of ASCTs for patients with multiple myeloma,
Non-Hodgkin lymphoma/chronic lymphocytic leuke-
mia (CLL), or other diagnoses were not affected by the
increased number of infusion days prompted by the
policy change (Table 5). Engraftment times wereChange (n 5 325) Post-policy Change (n 5 519) P Value
(6) 122 (24) <.0001
(46) 256 (49) .32
(4.0) 3 (0.6) .0004
(8-41) [295] 14 (8-31) [495] .99
(5-45) [273] 12 (6-53) [454] .82
Change (n 5 82) Post-policy Change (n 5 125) P Value
(24) 115 (92)* <.0001
(73) 90 (72) .85
(10) 1 (1) .002
(8-41) [76] 14 (8-28) [121] .12
(7-43) [70] 13 (6-43) [109] .87
. (B) Patients with cryopreserved PBSC products containing a cumulative
SC products that only minimally exceeded the 1.63  109 TNC/kg limit.
of loss to follow-up.
Table 5. Engraftment Outcomes Based on Diagnosis
(A)
Pre-policy Change Post-policy Change P-Value
Median days to neutrophil engraftment (n evaluable)
Multiple myeloma 15 (117) 15 (223) .59
Non-Hodgkin lymphoma/CLL 13 (118) 13 (173) .99
Other diagnosis 14 (60) 12 (100) .07
Median days to platelet engraftment (n evaluable)
Multiple myeloma 11 (106) 11 (199) .62
Non-Hodgkin lymphoma/CLL 12 (111) 12 (158) .36
Other diagnosis 13 (56) 12 (97) .21
(B)
Pre-policy Change Post-policy Change P-Value
Median days to neutrophil engraftment (n evaluable)
Multiple myeloma 14 (19) 15 (44) .39
Non-Hodgkin lymphoma/CLL 14 (43) 14 (60) .40
Other diagnosis 13 (14) 13 (17) .60
Median days to platelet engraftment (n evaluable)
Multiple myeloma 14 (17) 12.5 (40) .09
Non-Hodgkin lymphoma/CLL 12 (41) 13 (54) .33
Other diagnosis 12.5 (12) 14 (15) .68
(C)
Pre-policy Cohort
Number of Infusions
Post-policy Cohort
Number of Infusions
1 2 >2 1 2 >2
Median days to neutrophil engraftment (n evaluable)
Multiple myeloma 14.5 (12) 14 (7) — 16 (1) 15 (37) 15 (6)
Non-Hodgkin lymphoma/CLL 14 (34) 14 (7) 14.5 (2) 16.5 (2) 14 (33) 14 (25)
Other diagnosis 14 (11) 11 (3) — 10 (5) 12.5 (6) 16.5 (6)
Median days to platelet engraftment (n evaluable)
Multiple myeloma 15 (12) 12 (5) — 20 (1) 12 (34) 15 (5)
Non-Hodgkin lymphoma/CLL 12 (34) 14.5 (6) 12 (1) 11.5 (2) 12 (31) 13 (21)
Other diagnosis 12.5 (10) 16.5 (2) — 12 (5) 21 (5) 14 (5)
CLL indicates chronic lymphocytic leukemia; TNC, total nucleated cell.
(A) All ASCTs during the study period. (B) ASCTs with cryopreserved PBSC products containing a cumulative TNC dose of >1.63 109/kg. (C) ASCTs
with cryopreserved PBSC products containing a cumulative TNC dose of >1.63  109/kg with multiday infusions
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groups who received .1.63  109 TNC/kg; however,
more rigorous statistical analyses of the potential ef-
fects of multiday infusions were precluded by small
numbers (Table 5B and C).
Cost Analysis
There were no significant differences between in-
patient and outpatient costs for the first 3 months after
ASCT between the transplantations in pre and postpo-
licy cohorts (Table 6). The overall costs for ASCTs in
the postpolicy cohort, with products containing.1.63
 109 TNC/kg and for those patients whose infusions
were given overmultiple days, were similar to the over-
all costs for prepolicy ASCTs with high product TNCcontent and for those patients whose infusions were
usually completed in 1 day (Table 6B).DISCUSSION
The overall incidence of all adverse events associ-
ated with autologous PBSC infusions reported in the
literature ranges from 13.5% to 67.3% [4,8,16,17].
More severe infusion-related events occur in the range
of 0.4%, as reported by Graves et al. [26]. Multiple
studies have shown persistence of these AEs even after
depletion of DMSO, and as such, these complications
have been attributed to the nucleated cell and/or gran-
ulocyte content of the cryopreserved apheresis prod-
uct. In fact, Calmels et al. [16] reported strong
Table 6. Comparison of Costs for 3 Months Postautologous Transplantation
(A)
Pre-policy Change Post-policy Change
P ValueN Median Cost* (Range) N Median Cost* (Range)
Inpatient 94 68.8 (8.7-223.7) 170 65.4 (22.3-267.7) .76
Outpatient 119 58.8 (21.0-330.8) 207 58.5 (0.3-294.0) .57
(B)
Pre-policy Change Post-policy Change
P ValueN Median Cost* (Range) N Median Cost* (Range)
Inpatient 32 65.1 (8.7-223.7) 47 69.2 (31.7-159.6) .67
Outpatient 29 59.3 (30.3-147.4) 46 68.3 (2.1-214.5) .25
(A) All ASCTs during the study period. (B) ASCTs with cryopreserved PBSC products containing a cumulative TNC dose of >1.63  109/kg.
*Cost in $1000s.
226 Biol Blood Marrow Transplant 18:220-228, 2012N. Khera et al.correlations not only between the occurrence but also
severity of infusion-related AEs with a high prefreeze
product granulocyte content and low postthaw
CD451 cell viability. Together, these observations
suggest that granulocytes, both viable and dead cells,
and cellular debris (membranes, granule contents,
and cytokines) play a direct causal role in the pathobi-
ology of infusion-related toxicities.
Investigators have suggested a variety of ways to ad-
dress the issue of toxicity because of high granulocyte
content of the cryopreserved PBSC product. At the
time of collection, obtaining high-quality apheresis
products with minimal contamination by mature mye-
loid cells is desirable [4,8,16,17]. Poor mobilization of
CD341 progenitor cells is a major factor that can
negatively affect the quality of the apheresis product.
Difficulty mobilizing CD341 cells has also been
described as a poor prognostic factor in terms of
predicting engraftment delay and worse event-free
survival (EFS), despite transplanting adequate
CD341 cell doses [27,28]. High peripheral blood
WBC and granulocyte counts as seen with
mobilization using only hematopoietic growth-factor
(GF) stimulation are associated with decreased
CD341 cell collection efficiency and a higher rate of
granulocyte contamination of the PBSC product
[29,30]. Cooling et al. [24] recently reported that che-
motherapy and GF mobilization along with manual
collection on the COBE Spectra instrument with the
WBC kit improved CD341 cell yield and decreased
the granulocyte content and infusion reaction rates
compared with mobilization with GF only and use of
AUTO-kits. This raises the consideration that differ-
ent apheresis devices, collection parameters, or flow
rates may be employed to optimize CD341 cell collec-
tion efficiency and reduce the amount of granulocytes
in the final product to decrease cryopreserved PBSC
product infusional toxicity. Plerixafor is a relatively
new agent that is being increasingly used to improve
CD341 cell mobilization and collection in heavily pre-
treated patients who are poor mobilizers [31-33].These and other interventions that improve graft
quality without the need for repeated apheresis
procedures may help decrease infusion-related AEs be-
cause of cryopreserved product granulocyte contami-
nation.
This study demonstrates that spreading out the in-
fusions of cryopreserved PBSC products for ASCT
over multiple days can significantly reduce the inci-
dence of grade 3-5 infusion-related AEs without
compromising the speed of hematopoietic recovery.
The days to neutrophil and platelet engraftment
were comparable in our pre-policy change and post-
policy change cohorts, regardless of whether the cu-
mulative PBSC product TNC content was above or
below our safety threshold of 1.63  109 TNC/kg.
Neutrophil and platelet engraftment times were simi-
lar for patients with myeloma, lymphoid malignancies,
or other diseases whether they required 1 day for prod-
uct infusion or more than 1 day. Splitting the infusions
over multiple days does impose an increased workload
for the cell therapy facility and the nursing staff. How-
ever, this did not translate into significantly increased
costs to third-party payers among the overall post-
policy change cohort or among the subset of patients
with high product TNC content who were subject to
multiple days of infusion. We believe that the in-
creased safety from severe infusion-related adverse
events ultimately compensates for the logistic chal-
lenges of multiday infusions.
Our study does have some limitations. Althoughwe
assessed days to platelet and neutrophil engraftment,
we did not specifically evaluate for any effects of limit-
ing the daily TNC dose on immune reconstitution,
infectious complications, or days of hospitalization. Al-
though our decision to split the infusions was based on
daily TNC dose, this also resulted in lowering the daily
DMSO exposure, which might have accounted for the
decrease in SAEs. However, 4% of patients in the pre-
policy cohort suffered grade 3-5 AEs, despite limiting
the daily volume/kg of product to at or below the
well-accepted standard limit of 10 mL/kg to restrict
Biol Blood Marrow Transplant 18:220-228, 2012 227Safety of Autologous PBSC Product InfusionstheDMSOexposure [21]. To address this question fur-
ther, we performed a multivariable analysis and found
that, although volume alone was a significant predictor
of infusion-related SAEs (P\ .0001), after adjustment
for TNC it lost all significance (P 5 .54). In contrast,
TNC, both alone and after adjustment for volume,
was a highly significant predictor. Another limitation
was that in examining costs, the estimates in the study
represent costs of autologous stem cell transplants at
our center and may not be representative, although
they are in the range of overall costs as suggested by
theNational BoneMarrowTransplant LINK resource
guide in the United States [34].
Because of a small number of patients receiving
plerixafor, we could not assess its impact on the num-
ber of TNCs in the collection product or whether it
might eliminate the need for multiday infusions.
We also acknowledge that the adverse effects of
high TNC and granulocytes in the thawed apheresis
product may be related to as-yet undefined risk fac-
tors in patients with certain disease characteristics.
It is possible that factors predisposing a patient to
poor mobilization and/or correlating with a pretrans-
plantation comorbidity profile, especially cardiovas-
cular disease or infections, might also predispose
a patient to more severe infusion-related toxicity.
Age, gender, and patient diagnosis have been re-
ported as predictors of AEs in other studies [4,8,17].
Bojanic et al. [4] identified female gender and diagno-
sis of multiple myeloma in addition to granulocyte
content as factors predicting infusion-related toxic-
ity. The effect of age is not so clear, as Milone et al.
[8] reported increasing incidence of AEs with
increasing age, whereas Cordoba et al. [17] found in-
creased age to be protective against occurrence of
AEs.
In conclusion, limiting the daily dose of infused
TNC/kg in cryopreserved PBSC products for
ASCT resulted in a significant reduction in grade 3-5
infusion-related SAEs. Although this practice trans-
lated into an increased frequency ofmultiday infusions,
the kinetics of post-transplantation hematopoietic re-
covery and the overall costs of transplantation were
not affected by this safety measure.
Our study sets the stage for continued evaluation
of interventions and techniques at the time of collec-
tion to procure a high-quality apheresis product
that minimizes the chance of infusion-related com-
plications and improves the safety and outcomes
of autologous transplantation. Further research is
needed to study efficacy and compare costs of these
techniques and strategies. Future investigations
should also attempt to identify patients who may be
at highest risk for AEs, especially those with comor-
bidities or poor mobilization, because they might
benefit the most from a cost-effective alternative
approach.ACKNOWLEDGMENTS
Financial disclosure: This work was supported by
the following grants: CA 15704, CA 18029, and
DK56465.REFERENCES
1. Alessandrino P, Bernasconi P, Caldera D, et al. Adverse events
occurring during bone marrow or peripheral blood progenitor
cell infusion: analysis of 126 cases. Bone Marrow Transplant.
1999;23:533-537.
2. Bauwens D, Hantson P, Laterre PF, et al. Recurrent seizure and
sustained encephalopathy associated with dimethylsulfoxide-
preserved stem cell infusion. Leuk Lymphoma. 2005;46:1671-1674.
3. BenekliM, Anderson B,WentlingD, Bernstein S, CzuczmanM,
McCarthy P. Severe respiratory depression after
dimethylsulphoxide-containing autologous stem cell infusion
in a patient with AL amyloidosis. Bone Marrow Transplant.
2000;25:1299-1301.
4. Bojanic I, Cepulic BG, Mazic S, Batinic D, Nemet D, Labar B.
Toxicity related to autologous peripheral blood haematopoietic
progenitor cell infusion is associated with number of granulo-
cytes in graft, gender and diagnosis of multiple myeloma. Vox
Sang. 2008;95:70-75.
5. Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW.
Clinical toxicity of cryopreserved bone marrow graft infusion.
Blood. 1990;75:781-786.
6. Fois E, Desmartin M, Benhamida S, et al. Recovery, viability and
clinical toxicity of thawed and washed haematopoietic progenitor
cells: analysis of 952 autologous peripheral blood stem cell trans-
plantations. Bone Marrow Transplant. 2007;40:831-835.
7. Hoyt R, Szer J, Grigg A. Neurological events associated with
the infusion of cryopreserved bone marrow and/or peripheral
blood progenitor cells. Bone Marrow Transplant. 2000;25:
1285-1287.
8. Milone G, Mercurio S, Strano A, et al. Adverse events after in-
fusions of cryopreserved hematopoietic stem cells depend on
non-mononuclear cells in the infused suspension and patient
age. Cytotherapy. 2007;9:348-355.
9. Rapoport AP, Rowe JM, PackmanCH,Ginsberg SJ. Cardiac ar-
rest after autologous marrow infusion. Bone Marrow Transplant.
1991;7:401-403.
10. Rowley S, MacLeod B, Heimfeld S, Holmberg L, Bensinger W.
Severe central nervous system toxicity associated with the infusion
of cryopreserved PBSC components. Cytotherapy. 1999;1:311-317.
11. Smith DM, Weisenburger DD, Bierman P, Kessinger A,
Vaughan WP, Armitage JO. Acute renal failure associated
with autologous bone marrow transplantation. Bone Marrow
Transplant. 1987;2:195-201.
12. Stroncek DF, Fautsch SK, Lasky LC, Hurd DD, Ramsay NK,
McCullough J. Adverse reactions in patients transfused with cry-
opreserved marrow. Transfusion. 1991;31:521-526.
13. Windrum P, Morris TC. Severe neurotoxicity because of di-
methyl sulphoxide following peripheral blood stem cell trans-
plantation. Bone Marrow Transplant. 2003;31:315.
14. Zambelli A, Poggi G, Da Prada G, et al. Clinical toxicity of cry-
opreserved circulating progenitor cells infusion. Anticancer Res.
1998;18:4705-4708.
15. Zenhausern R, Tobler A, Leoncini L, Hess OM, Ferrari P. Fatal
cardiac arrhythmia after infusion of dimethyl sulfoxide-
cryopreserved hematopoietic stem cells in a patient with severe
primary cardiac amyloidosis and end-stage renal failure. Ann
Hematol. 2000;79:523-526.
16. Calmels B, Lemarie C, Esterni B, et al. Occurrence and severity
of adverse events after autologous hematopoietic progenitor cell
infusion are related to the amount of granulocytes in the apher-
esis product. Transfusion. 2007;47:1268-1275.
17. CordobaR, Arrieta R, Kerguelen A,Hernandez-Navarro F. The
occurrence of adverse events during the infusion of autologous
228 Biol Blood Marrow Transplant 18:220-228, 2012N. Khera et al.peripheral blood stem cells is related to the number of granulo-
cytes in the leukapheresis product. Bone Marrow Transplant.
2007;40:1063-1067.
18. Donmez A, Tombuloglu M, Gungor A, Soyer N, Saydam G,
Cagirgan S. Clinical side effects during peripheral blood pro-
genitor cell infusion. Transfus Apher Sci. 2007;36:95-101.
19. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al.
Early and fatal immune haemolysis after so-called ‘‘minor’’
ABO-incompatible peripheral blood stem cell allotransplanta-
tion. Bone Marrow Transplant. 1997;19:1155-1156.
20. Salmon JP,Michaux S, Hermanne JP, et al. Delayedmassive im-
mune hemolysis mediated by minor ABO incompatibility after
allogeneic peripheral blood progenitor cell transplantation.
Transfusion. 1999;39:824-827.
21. Sauer-Heilborn A, Kadidlo D, McCullough J. Patient care dur-
ing infusion of hematopoietic progenitor cells. Transfusion.
2004;44:907-916.
22. Schwella N, Zimmermann R, Heuft HG, et al. Microbiologic
contamination of peripheral blood stem cell autografts. Vox
Sang. 1994;67:32-35.
23. Cancer Therapy Evaluation Program. Common Terminology Cri-
teria for Adverse Events v3.0. Bethesda, MD:National Cancer In-
stitute; 2003.
24. Cooling L, Hoffmann S, Herrst M, Muck C, Armelagos H,
Davenport R. A prospective randomized trial of two popular
mononuclear cell collection sets for autologous peripheral blood
stem cell collection in multiple myeloma. Transfusion. 2010;50:
100-119.
25. Rowley SD, Prather K, Bui KT, AppelM, Felt T, BensingerWI.
Collection of peripheral blood progenitor cells with an auto-
mated leukapheresis system. Transfusion. 1999;39:1200-1206.
26. Graves VDC, Abonour R, McCarthy LJ. How to ensure safe
and well-tolerated stem cell infusions. Transfusion. 1998;
38(Suppl):30S.27. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an
independent prognostic factor in patients with malignant
lymphomas treated by peripheral blood stem cell transplanta-
tion. Bone Marrow Transplant. 2006;37:719-724.
28. Tomblyn M, Burns LJ, Blazar B, et al. Difficult stem cell
mobilization despite adequate CD341 cell dose predicts short-
ened progression free and overall survival after autologous
HSCT for lymphoma.BoneMarrow Transplant. 2007;40:111-118.
29. Burgstaler JEPA, Winter JL. Effects of high whole blood flow
rates and high peripheral WBC on CD341 yield and cross-
cellular contamination. Cytotherapy. 2003;5:446.
30. Gidron A, Verma A, Doyle M, et al. Can the stem cell mobiliza-
tion technique influence CD341 cell collection efficiency of
leukapheresis procedures in patients with hematologic malig-
nancies? Bone Marrow Transplant. 2005;35:243-246.
31. Duarte RF, Shaw BE, Marin P, et al. Plerixafor plus granulocyte
CSF canmobilize hematopoietic stem cells frommultiplemyeloma
and lymphoma patients failing previous mobilization attempts: EU
compassionate use data. Bone Marrow Transplant. 46:52-58.
32. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and
preliminary efficacy of plerixafor (Mozobil) in combination
with chemotherapy and G-CSF: an open-label, multicenter,
exploratory trial in patients with multiple myeloma and
non-Hodgkin’s lymphoma undergoing stem cell mobilization.
Bone Marrow Transplant. 45:39-47.
33. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor
in non-Hodgkin’s lymphoma and multiple myeloma patients to
increase the number of peripheral blood stem cells when given
a mobilizing regimen of G-CSF: implications for the heavily
pretreated patient. Biol Blood Marrow Transplant. 2009;15:
249-256.
34. National BoneMarrowTransplant LINK resource guide. Avail-
able from: http://www.nbmtlink.org/resources_support/rg/rg_
costs.htm). Accessed January 27, 2011.
